In the case of BiKEs, one of the variable antibody domains recognizes CD16 and the other a targeted tumor antigen (242), whereas, TriKEs, in addition to these two domains, have an interleukin 15 (IL15) element that connects the two different antibody domains. This evidence concerns the gene IL15 and neoplasm.